SCHEMBL2854048

SCHEMBL2854048

CS(=O)(=O)c1cccc(NC(=O)Nc2cnn(-c3ccc(Cl)cc3)c2C(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.50
NPSR1 Q6W5P4 3/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
CNR1 P21554 1/20 0.47
CCR1 P32246 1/20 0.47
CA2 P00918 3/20 0.45
CA1 P00915 2/20 0.45
CA7 P43166 2/20 0.45
CA4 P22748 1/20 0.45
CA9 Q16790 2/20 0.44
IDH2 P48735 2/20 0.43
EPHX2 P34913 2/20 0.43
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
RIPK1 Q13546 1/20 0.43
MAPK14 Q16539 1/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2852152 0.87 MAPT (0.56) MAPTNPSR1NPC1RAB9ALMNA
SCHEMBL2857713 0.86 CCR1 (0.49) MAPTNPC1RAB9ACCR1LMNA
SCHEMBL13513684 0.86 CCR1 (0.54) MAPTCCR1KEAP1NFE2L2
SCHEMBL14539381 0.85 CCR1 (0.42) MAPTNPSR1NPC1RAB9ACNR1
SCHEMBL2854169 0.84 MAPT (0.56) MAPTNPSR1NPC1RAB9AMAPK14
SCHEMBL2855798 0.83 MAPT (0.45) MAPTNPSR1CNR1CCR1CA2
SCHEMBL2858063 0.82 MAPT (0.57) MAPTNPSR1NPC1RAB9ACCR1
SCHEMBL2857105 0.81 MAPT (0.56) MAPTNPSR1NPC1RAB9ACNR1
SCHEMBL2855981 0.79 MAPT (0.60) MAPTNPSR1NPC1RAB9ACNR1
SCHEMBL5676798 0.78 KEAP1 (0.55) RAB9AKEAP1NFE2L2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
EP-1451160-A4 PYRAZOLE-AMIDES AND-SULFONAMIDES ICAGEN INC (US) 2005-04-20 EP disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed
EP-1451160-A2 PYRAZOLE-AMIDES AND-SULFONAMIDES Icagen, Inc. (US) 2004-09-01 EP disclosed
WO-2003037274-A2 PYRAZOLE-AMIDES AND-SULFONAMIDES ICAGEN, INC. (US) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 MAPT 3590/4885NPSR1 420/4885NPC1 3322/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 MAPT 3590/4885NPSR1 420/4885NPC1 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.